Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Blinken calls for closer global cooperation on tackling synthetic drugs

Published 15/03/2024, 13:22
Updated 15/03/2024, 18:50
© Reuters. U.S. Secretary of State Antony Blinken delivers remarks at the 67th Session of the UN Commission on Narcotic Drugs at Vienna International Centre, in Vienna, Austria March 15, 2024. REUTERS/Evelyn Hockstein/Pool

By Humeyra Pamuk and Francois Murphy

VIENNA (Reuters) - U.S. Secretary of State Antony Blinken on Friday called for greater international cooperation to fight the booming trafficking of illicit synthetic drugs such as fentanyl, the leading cause of overdose deaths in his country.

He was speaking at an annual meeting of the U.N. Commission on Narcotic Drugs (CND), which reviews global drug regulation and each year adds new so-called precursor chemicals - ingredients used to make illicit drugs - to international lists known as schedules to place strict controls on their trade.

"More than 40% of the American people know someone who has died from an opioid overdose. Synthetic drugs are now the number one killer of Americans aged 18 to 45," Blinken said in a speech to the two-day "high-level segment" of the CND.

While the drugs and the scale of the problem may vary by country, "in every region, use, dependence, overdose deaths by synthetic drugs are rising rapidly", he said.

"My message to this gathering is urgent. If we want to change the trajectory of this crisis, there is only one way to succeed, and that's together," he said.

This year the CND, which is meeting in Vienna until the end of next week, is considering adding two fentanyl precursors to the schedules, which the United States supports. While such "scheduling" is necessary, U.N. officials say the process is a losing battle.

"The current international scheduling system is absolutely very effective in putting one substance out of the reach of illicit drug traffickers, but unfortunately is very little efficient in slowing down the pace of evolution of illicit drug manufacturing," Antonio Mazzitelli of the International Narcotics Control Board, which monitors compliance with the schedules, told a separate event at the CND meeting.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

"As soon as a substance is put under control, another one replaces it," he added.

Blinken echoed that sense of facing a cunning opponent.

"The criminal groups that produce these drugs are agile. When one country cracks down on the production of a synthetic drug, or the chemical precursors that go into making them, criminals quickly find another place to produce them," he said.

Through a combination of other initiatives, however, such as closer cooperation with allies and working with social media companies to disrupt the synthetic drug trade online, there have been some successes, he said.

"We have recent data that suggests that for the first time in years, the number of Americans who died of overdoses did not increase significantly. The number has leveled off. Now with one American still dying of a drug overdose every five minutes, our work is far from finished," Blinken said.

"But the change suggests that the steps we're taking, many in partnership with countries here in this room, are making a difference, are starting to turn the tide," he added.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.